Category - Markets

Ladenburg Thalmann initiated coverage of Zynerba Pharmaceuticals (NASDAQ:ZYNE) with a “buy” rating and $25.50 price target. The stock closed at $12.07 on Jan. 26. Zynerba is developing two clinical-stage synthetic...

Stifel launched coverage of Protagonist Therapeutics (NASDAQ:PTGX) with a “buy” rating and a $32 target price. The stock closed at $19.23 on Jan. 26. Protagonist is leveraging its proprietary peptide technology platform...

Maxim Group initiated coverage of Atossa Genetics (NASDAQ:ATOS) with a “buy” rating and 12-month price target of $2. The stock closed at 33 cents on Jan. 25. Atossa is developing an oral formulation of endoxifen for...

RBC Dominion Securities downgraded TSO3 (TSX:TOS) to “sector perform” from “outperform” and slashed its price target to $2 from $4.25 after the company entered into a new co-distribution agreement with Getinge to sell...

Ladenburg Thalmann initiated coverage of Flex Pharma (NASDAQ:FLKS) with a “buy” rating and $12 price target. The stock closed at $4.02 on Jan. 24. Flex is leveraging its research in muscle cramping as a disorder of...

Canaccord Genuity resumed coverage of Neovasc (NASDAQ:NVCN) with a “buy” rating and price target of $1.05. The stock closed at 53 cents on Jan. 18. Analyst Jason Mills writes that Neovasc recently reported acceleration...

Mackie Research Capital resumed coverage of WeedMD (TSXV:WMD) and raised its price target to $4 from $3 after the company completed a $34.5-million offering of units. The stock closed at $2.60 on Jan. 16. WeedMD is a...

Ladenburg Thalmann downgraded Aradigm (NASDAQ:ARDM) to “neutral” from “buy” and removed its previous $10 price target. The stock closed at $3.42 on Jan. 16. On Jan 11, the Antimicrobial Drugs Advisory Committee of the...

William Blair initiated coverage of Pieris Pharmaceuticals (NASDAQ:PIRS) with an “outperform” rating. The stock closed $7.46 on Jan. 16. Analyst Matthew Phipps writes that the company’s Anticalin platform continues to...

For 2018, CIBC World Markets is recommending investors hold a basket of healthcare stocks that include a combination of more speculative small and midcap companies with selected large caps. Analyst Prakash Gowd writes...